Article Text
PDF
Abstract
Introduction/Background The gold standart of advanced-stage ovarian cancer treatment is debulking surgery and systematic chemotherapy. However, alternative ways of drug delivery are exist and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) is one of such methods.
Since June 2020 we have started to perform these procedures for the purpose of upgrade the medical care for women with advanced-stage ovarian cancer.
Results Sixty eight cytoreduction procedures were made from June 2020 through April 2023 and HIPEC was considered at the time of debulking surgery in twelve cases. There were nine patients with stage 3B, fifty five patients with stage 3C, two patients with stage 4A and two patients with recurrence of disease. The mean time of procedure was 558 minutes in debulking surgery plus HIPEC group and 382 minutes in the group of debulking surgery only. The median postoperative hospital stay was 21,9 days in the group with HIPEC and 13,4 days in the group without HIPEC. It was performed 22 optimal debulking procedures with the completeness of cytoreduction score (CC) – 1, and 46 complete debulking procedures CC – 0. The average score of peritoneal carcinomatosis index was 11,7. The percentage of patients who had adverse events of grade 3 or 4 in surgery with HIPEC group was 25%, and in surgery group without HIPEC – 21,4%. The postoperative mortality was 2,9% (two patients). Out of 68 patients 15 were relapsed (22%) within 5–24 months (average time 11,8 months), three relapses were in HIPEC group (25%) and twelve without HIPEC (21,4%). Three of them have died (4,4%), two in HIPEC group und 1 without HIPEC.
Conclusion Overall, our data shows that addition HIPEC to the debulking procedure extends mean time of procedure, postoperative hospital stay, does not increase risk of adverse events grade 3 or 4 but also does not improve oncological outcomes
Disclosures All authors have no conflicts of interest to declare.